Literature DB >> 11752125

Morphine tolerance in spinal cord is due to interaction between mu- and delta-receptors.

Pal Riba1, Yong Ben, Andrew P Smith, Susanna Furst, Nancy M Lee.   

Abstract

When the opioid agonist morphine is given chronically and systemically to mice by pellet implantation for 3 days, the animals develop substantial tolerance to the antinociceptive effect of a test dose of morphine given systemically. When the test dose is administered to the spinal cord, however, very little tolerance is observed. We tested six strains of mice differing in the degree to which they develop systemic tolerance to morphine and found that none of them developed significant tolerance to spinal morphine. However, most of these strains did develop substantial spinal tolerance to antinociception induced by the selective mu-agonist [D-Ala(2),N-Me-Phe(4),Gly(5)-ol]-enkephalin (DAMGO) and by the selective delta-agonist [D-Pen(2),D-Pen(5)]-enkephalin (DPDPE). Moreover, in naïve animals, the antinociceptive effect of both DAMGO and DPDPE was blocked by D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH(2), a selective mu-antagonist, indicating that both agonists mediate antinociception in the spinal cord through mu-receptors. In addition to directly mediating antinociception, however, DPDPE potentiated the antinociceptive activity of DAMGO in the spinal cord of naïve animals, and this antinociception was blocked by the delta-antagonist H-TyrTicPsi[CH(2)NH]Phe-Thr-OH (TIPPpsi), indicating mediation through delta-receptors. In contrast, in tolerant animals, TIPPpsi enhanced the antinociception of DAMGO. These results thus demonstrate not only that mu- and delta-opioid receptors interact in naïve animals, but that the nature of this interaction changes during tolerance, from a potentiation to an inhibition. The lack of tolerance to spinal morphine may result from the ability of morphine to act as a partial antagonist at delta-receptors.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11752125     DOI: 10.1124/jpet.300.1.265

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  15 in total

1.  Up-regulation of mu-opioid receptors in the spinal cord of morphine-tolerant rats.

Authors:  Subrata Basu Ray; Himanshu Gupta; Yogendra Kumar Gupta
Journal:  J Biosci       Date:  2004-03       Impact factor: 1.826

2.  How to design an opioid drug that causes reduced tolerance and dependence.

Authors:  Amy Chang Berger; Jennifer L Whistler
Journal:  Ann Neurol       Date:  2010-05       Impact factor: 10.422

3.  Receptor heterodimerization leads to a switch in signaling: beta-arrestin2-mediated ERK activation by mu-delta opioid receptor heterodimers.

Authors:  Raphael Rozenfeld; Lakshmi A Devi
Journal:  FASEB J       Date:  2007-03-23       Impact factor: 5.191

Review 4.  Engineering endomorphin drugs: state of the art.

Authors:  Lawrence H Lazarus; Yoshio Okada
Journal:  Expert Opin Ther Pat       Date:  2012-01-04       Impact factor: 6.674

5.  Sex differences in kappa opioid receptor inhibition of latent postoperative pain sensitization in dorsal horn.

Authors:  Lilian Custodio-Patsey; Renée R Donahue; Weisi Fu; Joshua Lambert; Bret N Smith; Bradley K Taylor
Journal:  Neuropharmacology       Date:  2019-07-25       Impact factor: 5.250

6.  In vivo activation of a mutant mu-opioid receptor by naltrexone produces a potent analgesic effect but no tolerance: role of mu-receptor activation and delta-receptor blockade in morphine tolerance.

Authors:  Sabita Roy; Xiaohong Guo; Jennifer Kelschenbach; Yuxiu Liu; Horace H Loh
Journal:  J Neurosci       Date:  2005-03-23       Impact factor: 6.167

7.  Essential role of mu opioid receptor in the regulation of delta opioid receptor-mediated antihyperalgesia.

Authors:  L Gendron; J E Pintar; C Chavkin
Journal:  Neuroscience       Date:  2007-10-05       Impact factor: 3.590

8.  Tuned-Affinity Bivalent Ligands for the Characterization of Opioid Receptor Heteromers.

Authors:  Jessica H Harvey; Darcie H Long; Pamela M England; Jennifer L Whistler
Journal:  ACS Med Chem Lett       Date:  2012-08-09       Impact factor: 4.345

9.  Inhibition of the development of morphine tolerance by a potent dual mu-delta-opioid antagonist, H-Dmt-Tic-Lys-NH-CH2-Ph.

Authors:  Yunden Jinsmaa; Ewa D Marczak; Gianfranco Balboni; Severo Salvadori; Lawrence H Lazarus
Journal:  Pharmacol Biochem Behav       Date:  2008-10       Impact factor: 3.533

10.  TRPV1 receptor in expression of opioid-induced hyperalgesia.

Authors:  Anna Vardanyan; Ruizhong Wang; Todd W Vanderah; Michael H Ossipov; Josephine Lai; Frank Porreca; Tamara King
Journal:  J Pain       Date:  2008-09-06       Impact factor: 5.820

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.